The EU's biosimilar insulin guideline is finally ready
This article was originally published in Scrip
Executive Summary
The European Medicines Agency has published the final version of its revised guideline on biosimilar products containing recombinant human insulin and insulin analogues, following a drafting and consultation process that lasted more than two years.